# OnCo record prostate-failed-programmes (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/prostate-failed-programmes/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "prostate-failed-programmes" ;
  schema:name "Prostate cancer programmes that failed, and what each failure taught"@en ;
  schema:alternateName "prostate cancer drug failures"@en, "negative prostate trials"@en, "prostate cancer graveyard"@en ;
  schema:description "More large prostate cancer trials have failed than succeeded. The failures cluster: immunotherapy in unselected men, drugs aimed at blood vessels, drugs aimed at bone signalling, and drugs that improved scans without extending life."@en ;
  schema:url <https://onco.cc/terms/prostate-failed-programmes/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41591-021-01600-6>, <https://doi.org/10.1016/S1470-2045(15)70027-6>, <https://doi.org/10.1200/JCO.2015.65.5597>, <https://doi.org/10.1016/S1470-2045(18)30860-X> ;
  onco:status "established" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/antisense-sirna/>, <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/ar-v7/> ;
  onco:trials <https://onco.cc/trials/imbassador250/>, <https://onco.cc/trials/keynote-641/>, <https://onco.cc/trials/keynote-921/>, <https://onco.cc/trials/keynote-991/>, <https://onco.cc/trials/ca184-043-ipilimumab/>, <https://onco.cc/trials/calgb-90401/>, <https://onco.cc/trials/comet-1/>, <https://onco.cc/trials/swog-s0421-atrasentan/>, <https://onco.cc/trials/enthuse-m1-zibotentan/>, <https://onco.cc/trials/ready-dasatinib/>, <https://onco.cc/trials/tasquinimod-10tasq10/>, <https://onco.cc/trials/elm-pc-4-orteronel/>, <https://onco.cc/trials/synergy-custirsen/>, <https://onco.cc/trials/affinity-custirsen/>, <https://onco.cc/trials/armor3-sv/>, <https://onco.cc/trials/prospect-prostvac/>, <https://onco.cc/trials/era-223/> .